CALGARY, May 3, 2016 /PRNewswire/ - Oncolytics
Biotech® Inc. ("Oncolytics" or the
"Company") (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) announced
today that its 2016 Annual Meeting of Shareholders will be held on
Thursday, May 5th, 2016 at
4:00 pm ET (2:00 pm MT) at the Toronto Region Board of Trade
located at First Canadian Place, Suite 350, 77 Adelaide St. West,
Toronto, Ontario.
Following the business portion of the meeting, Dr. Brad Thompson, President and CEO of Oncolytics,
will discuss recent progress in the development of
REOLYSIN® as a potential cancer therapeutic.
A live audio webcast of Dr. Thompson's presentation will begin
at approximately 4:15 pm ET
(2:15 pm MT) and be available at:
http://event.on24.com/r.htm?e=1162870&s=1&k=8D8411394AC01E5C5A9CDC57BFA2ED10
or on the company's website at www.oncolyticsbiotech.com. It is
recommended that listeners log on 10 minutes in advance of the
presentation to register and download any necessary software.
An audio replay will be accessible following the presentation
at:
http://www.oncolyticsbiotech.com/investor-centre/presentations/.
About Oncolytics Biotech Inc.
Oncolytics is a
Calgary-based biotechnology
company focused on the development of oncolytic viruses as
potential cancer therapeutics. Oncolytics' clinical program
includes a variety of later-stage, randomized human trials in
various indications using REOLYSIN®, its proprietary
formulation of the human reovirus. For further information about
Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release and the presentation related thereto
contain forward-looking statements, within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including the Company's belief as to
the potential of REOLYSIN® as a cancer therapeutic; the
Company's expectations as to the success of its research and
development programs in 2016 and beyond, the Company's planned
operations, the value of the additional patents and intellectual
property; the Company's expectations related to the applications of
the patented technology; the Company's expectations as to adequacy
of its existing capital resources; the design, timing, success of
planned clinical trial programs; and other statements related to
anticipated developments in the Company's business and technologies
involve known and unknown risks and uncertainties, which could
cause the Company's actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties
include, among others, the availability of funds and resources to
pursue research and development projects, the efficacy of
REOLYSIN® as a cancer treatment, the success and timely
completion of clinical studies and trials, the Company's ability to
successfully commercialize REOLYSIN®, uncertainties
related to the research and development of pharmaceuticals,
uncertainties related to the regulatory process and general changes
to the economic environment. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties
relating to the forward-looking statements. Investors are cautioned
against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward-looking
statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.